Related Experiment Videos

A new approach for realizing the "antioncogram"

P Köpf-Maier1

  • 1Institut für Anatomie, Freie Universität Berlin, Germany.

Life Sciences
|January 1, 1992
PubMed

Insights

This study introduces an organoid culture assay (OCA) to predict patient carcinoma drug response before chemotherapy. The assay tests drug sensitivity and resistance using patient tumor samples in vitro for personalized cancer treatment.

Area of Science:

  • Oncology
  • Cell Biology
  • Biotechnology

Background:

  • Carcinoma drug resistance poses a significant challenge in clinical chemotherapy.
  • Predicting individual patient response to chemotherapy is crucial for effective treatment.

Purpose of the Study:

  • To develop and validate an organoid culture assay (OCA) as an "antioncogram" for predicting patient-specific carcinoma drug sensitivity.
  • To establish an in vitro model for assessing drug resistance in human carcinomas prior to clinical application.

Main Methods:

  • Human carcinoma specimens were disaggregated into single cell suspensions and cultured as organoids on filter sheets.
  • Organoids were exposed to cytostatics (cisplatin) for 2-3 days.
  • Cytotoxic effects were quantified by measuring viable cell fraction (neutral red uptake) relative to total cell mass.

Main Results:

  • The organoid culture assay (OCA) successfully reflected experimentally induced cisplatin resistance in epidermoid hypopharynx carcinoma strains.
  • The assay demonstrated its suitability for rapid and feasible prediction of individual human carcinoma responses to chemotherapy.

Conclusions:

  • The organoid culture assay (OCA) serves as a viable "antioncogram" for personalized cancer therapy.
  • This in vitro method can guide clinical chemotherapy decisions by predicting drug sensitivity and resistance.

Related Concept Videos